Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
ZUG, Switzerland, March 2, 2016 -- Auris Medical Holding AG (Nasdaq: EARS) today announced that it will release its financial results for the fourth quarter and full year 2015, on Monday, March 14, 2016. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) to discuss Auris Medical's financial results for the fourth quarter and full year 2015 and provide a general business update.
Auris Medical further announced that it will hold its Annual General Meeting on April 8, 2016. Shareholders registered in the share ledger maintained by our transfer agent, American Stock Transfer & Trust Company, LLC, on April 4, 2016 are entitled to participate in and vote at the Annual General Meeting. Meeting materials will be mailed on or around March 14, 2016. The record date for "street name" holders is March 10, 2016. "Street name" holders should follow the instructions provided by their bank, broker or nominee to vote their shares.
Conference Call / Webcast Information
The call is scheduled for March 14, 2016 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time). To participate in this conference call, dial 1877 280 2296 (USA) or +1 646 254 3388 (International), and enter passcode 8927407. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at: www.aurismedical.com. A replay will be available approximately two hours following the live call also on the Company's website.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, [email protected]
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, [email protected]
HUG#1990658
